{
  "model": "gemini-3.1-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gemini-3-1-pro-preview-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 65186,
  "agentCostUsd": 0.1306242,
  "graderCostUsd": 0,
  "totalCostUsd": 0.1306242,
  "agentUsage": {
    "promptTokens": 34719,
    "cachedTokens": 5341,
    "responseTokens": 2566,
    "thinkingTokens": 3334,
    "totalTokens": 40619
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 34719,
    "cachedTokens": 5341,
    "responseTokens": 2566,
    "thinkingTokens": 3334,
    "totalTokens": 40619
  },
  "modelVersions": [
    "gemini-3.1-pro-preview"
  ],
  "agentFinalText": "I have successfully read the report and schemas, extracted the relevant information, and created all the required output files in JSON format. \n\nCompletion checklist:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"78 tumor-bearing mice pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"84 tumor-bearing mice pooled across matched controls.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"130 metastatic patients receiving ICI treatment, comprising vaccinated and unvaccinated subgroups.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "controls_or_null_results.0.evidence_line_ref: Invalid input: expected string, received array",
        "controls_or_null_results.1.evidence_line_ref: Invalid input: expected string, received array",
        "controls_or_null_results.2.evidence_line_ref: Invalid input: expected string, received array",
        "controls_or_null_results.3.evidence_line_ref: Invalid input: expected string, received array"
      ],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": [\"L36\"]\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": [\"L37\"]\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": [\"L38\"]\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": [\"L39\"]\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Vaccinated human patients show improved survival under ICI treatment.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination broadens the antigen display and MHC-I peptide repertoire.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Type I interferon signaling is mechanistically required for the tumor sensitization effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA vaccines may prime tumors for better immune checkpoint blockade responses\",\n  \"plain_language_summary\": \"Researchers have discovered that intratumoral delivery of mRNA vaccines can create a highly inflammatory state within tumors, specifically driven by type I interferon signaling. This inflammation enhances the processing and presentation of tumor antigens, making the cancer cells more visible to the immune system. As a result, the tumor's sensitivity to immune checkpoint inhibitor therapies, such as anti-PD-L1 drugs, is significantly increased. Both mouse models and retrospective human data indicate improved outcomes when these treatments are combined.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination triggers localized type I interferon signaling in tumors.\",\n    \"The mRNA vaccine expands the landscape of tumor proteins presented on the MHC-I peptidome.\",\n    \"Combining the mRNA vaccine with immune checkpoint inhibitors improves tumor control.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data analysis is completely retrospective and non-randomized.\",\n    \"Differences in vaccination timing and patient treatment history could introduce confounding.\",\n    \"Mouse model findings may not directly translate to complex human tumor microenvironments.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors\",\n      \"definition\": \"Drugs that block proteins from binding with their partners, allowing T cells to kill cancer cells.\"\n    },\n    {\n      \"term\": \"Intratumoral delivery\",\n      \"definition\": \"A method of administering a drug or vaccine directly into a tumor.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete set of peptides presented by MHC molecules on the surface of cells.\"\n    },\n    {\n      \"term\": \"Interferon signaling\",\n      \"definition\": \"A cellular communication process that alerts the immune system to the presence of pathogens or tumors.\"\n    }\n  ],\n  \"open_questions\": [\n    \"How will these findings translate into prospective randomized clinical trials?\",\n    \"Which specific tumor types are most responsive to intratumoral mRNA vaccination?\",\n    \"What is the optimal timing for administering the mRNA vaccine relative to immunotherapy?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 20,
    "failedCalls": 0,
    "toolsUsed": [
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-19T17:22:16.107Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-19T17:22:19.733Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-19T17:22:19.733Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-19T17:22:19.733Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-19T17:22:19.733Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-19T17:22:19.733Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-19T17:22:29.547Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-19T17:22:40.661Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-19T17:22:57.030Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-19T17:23:07.840Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
